Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ther Clin Risk Manag. 2007 Jun;3(3):441-8.

Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin.

Author information

  • 1Adnan Menderes University Medical Faculty, Department of Infectious Diseases and Clinical Microbiology Aydin, Turkey.

Abstract

Community-acquired pneumonia (CAP) is the cause of substantial morbidity, mortality, and resource utilization worldwide. When choosing an antimicrobial, effective treatment depends on proper patient evaluation and the identification of numerous risk factors, such as recent antibiotic exposure or the presence of comorbidity. Patients without any risk factor should be treated effectively with a narrow spectrum beta-lactam agent, like amoxicillin, or a macrolide. If a risk factor is present, agents with a broader spectrum of activity should be selected for the empirical therapy. The newer-generation quinolones are suitable agents with their excellent in vitro activity and pharmacodynamic-pharmacokinetic properties. They are not only active against susceptible CAP pathogens, but also against the resistant strains. Among the quinolones, gemifloxacin has the best in vitro activity. Its improved bioavailability, pharmacokinetic-pharmacodynamic properties, and safety profile make this agent an excellent option for the treatment of CAP.

KEYWORDS:

community-acquired pneumonia; gemifloxacin; treatment

PMID:
18488076
[PubMed]
PMCID:
PMC2386358
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk